Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (January 2021)
31 slides from Sernova Biotherapeutics's investor presentation, January 2021

Slide 1: The Path To A Regenerative Medicine Cure
SEOVF TRADED ON The Path To A Regenerative Medicine Cure Corporate Presentation January 2021

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward- looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expect

Slide 3: Regenerative Medicine - The Future Now
Regenerative Medicine - The Future Now Regenerative Medicine (RM) is a rapidly evolving field of science developing new therapeutic solutions to treat disease: ➢ with the repair or growth of new tissues & organs, i.e. organ regeneration ➢ repairing cells at the gene level to prevent disease, i.e. ge

Slide 4: Sernova: Innovator & Leader
Sernova: Innovator & Leader Publicly traded, clinical-stage RM therapeutics solution innovator & leader: ➢ Cell therapy therapeutics solution platform treating chronic diseases & enhancing daily QOL ➢ Integrated RM therapeutic solution (Cell Pouch™ + therapeutic cells or tissue + immune-protection)

Slide 5: Sernova's Platform Approach
Sernova’s Platform Approach Integrated RM Therapeutic Solution for 28% 40% Treatment of Chronic Diseases 32% Cell Pouch Therapeutic Cells Immune Protection Implantable proprietary medical Human cells (donor / stem) & Technologies to protect device that provides vascularized tissues that produce & re

Slide 6: Cell Pouch Manufacturing
Cell Pouch™ Manufacturing Manufacture of the Cell Pouch™ in multiple sized is conducted GMP by a US contract manufacturer in a Class VII Clean Room Product and process development is conducted in accordance with manufacturer’s Quality System • ISO 13485 • EU Medical Devices Regulation MDR 2017/745 •

Slide 7: Worldwide IP / Patent Portfolio
Worldwide IP / Patent Portfolio International patents & patent applications portfolio in multiple patent families with broad application & continued expansion: ➢ Composition & use of medical devices for delivery & cell transplantation ➢ Glucose responsive insulin secreting stem cell technologies ➢ L

Slide 8: Diabetes… Hope for a Functional Cure
Diabetes… Hope for a Functional Cure The Reality: Diabetes is one of the most prevalent diseases & pervasive medical problems impacting society & everyday quality of life (QOL) today ➢ 463 million affected worldwide and nearly 10% of these individuals have T1D (1) ➢ T1D represents a potential commer

Slide 9: Sernova Pipeline
Sernova Pipeline CELL POUCH PRE- DEVELOPMENT CANDIDATE CLINICAL PHASE I PHASE II PHASE III STAGE INDICATION HUMAN DONOR ISLETS, P H A S E I /I I I N I T I AT E D HYPOGLYCEMIA SYSTEMIC IMMUNE DEC 2018 UNAWARENESS PROTECTION T1D A N T I C I PAT E D 2 ND ALL INSULIN LOCALLY IMMUNE- A P P R O VA L F O R

Slide 10: Diabetes Market Opportunities
Diabetes Market Opportunities IP Status 2020 Potential Patient Population Potential Commercial Opportunity (before market access considerations) T1D Severe HU T1D Severe HU Device / Method T1D Severe HU All T1D T1D Severe HU All T1D with Human with Human Patent with iPSC with iPSC with iPSC with iPS

Slide 11: RM Diabetes Competitive Landscape
RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Financial Metrics Therapeutic C-peptide Levels Islet Engraftment Protection Technology (USD Millions) Measured in Bloodstream Demonstrated in Humans Phase I/II initiated late 2018 in T1D Interim data demons

Slide 12: RM Diabetes Competitive Landscape
RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Therapeutic C-peptide Levels Islet Engraftment Protection Technology Measured in Bloodstream Demonstrated in Humans Entered clinic end of 2020 for hemophilia A In experimental animal models, SLTx™ Sigilon b

Slide 13: Sernova Valuation Relative to Peers
Sernova Valuation Relative to Peers • Sernova’s peer group - SIGILON and SEMMA • SVA Advancements over Peer Group • Sernova US Phase I/II clinical trial with positive interim clinical results presented at ASTS Jan 15, 2021 vs. peer group lack of clinical data • Sernova: Diabetes + thyroid + hemophil

Slide 14: Cell Pouch Solves Device Conundrum
Cell Pouch Solves Device Conundrum The Device Conundrum “We thought the cells would be the hard part and focused our efforts there. It’s obvious now having a functional device will be the limiting factor and there are few current options.” Big Pharma executive at 2020 JPM The challenging device issu

Slide 15: Immune Protection
Immune Protection Conformal Coating Technologies: • Sernova’s proprietary cellular conformal coating technology - developed and optimized with years of research • It consists of a thin biocompatible porous polymer hydrogel coating surrounding therapeutic cells (islets, stem cells) • Proven to allow

Slide 16: Biologically Compatible Delivery Process
Biologically Compatible Delivery Process Cell Pouch Implantation & Therapeutic Cells Delivery Process Proprietary Cell Pouch is Therapeutics cells are Therapeutic cells release placed deep under the skin, transplanted directly into the missing proteins or allowing for vascularization & vascularized

Slide 17: Diabetes Clinical Progress Summary
Diabetes Clinical Progress Summary ➢ Completion of first-in-human proof-of-concept study for diabetic condition HU ➢ Clinical protocol & regulatory package development for US Ph I / II clinical trial for HU (T1D Study) Pre 2018 ➢ FDA IND clearance to commence T1D Study ➢ T1D Study funding grant awar

Slide 18: Diabetes First Clinical Indication: HU
Diabetes First Clinical Indication: HU Hypoglycemia Hypoglycemia unawareness unawareness (HU), the(HU), most the most critical critical unmet needunmet needaffects in diabetes, in diabetes, 15% of T1D affects patients 15% (~240K of T1Dinpatients patients (~240 K patients in the US alone) the US alon

Slide 19: US Ph I/II Study Design
US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Study Design: Company-sponsored IND. Open-label, single-arm study. Human donor islets are transplanted into the Cell Pouch after implantation & stable anti-rejection medication activity has been established. Primary Objective: T

Slide 20: US Ph I/II Safety
US Ph I/II Safety US Ph I/II Safety, Tolerability, Efficacy Study Incidence & severity of adverse events associated with Cell Pouch were monitored: ➢ No incidences of AEs or SAEs determined to be probable or highly probable to the Cell Pouch ➢ Cell Pouch well-tolerated & safe during the implant & th

Slide 21: US Ph I/II Case Study Early Findings
US Ph I/II Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study First Patient Observed Data Presented by Clinical Investigator* Early Efficacy Findings Islet Transplant Status: Before 3 Mo. After Bodyweight 83kg 73kg Hemoglobin A1C 6.5 5.6 90-day post-transplant glucose toleranc

Slide 22: US Ph I/II Case Study Early Findings
US Ph I/II Case Study Early Findings Improvement in ALL CGM Parameters Blood Glucose Over Time (mg/dL) Baseline: More excursions seen pre-transplant Parameter Baseline Post-transplant (90 days) High Glucose Value (mg/dL) 285 231 Low Glucose Value (mg/dL) 50 66* # Glucose Excursions 15 3 # High Excur

Slide 23: US Ph I/II 90-Days Post Transplant
US Ph I/II 90-Days Post Transplant Achievement of Secondary Endpoint “Survival of endocrine tissue in the Cell Pouch™ (defined by positive staining of islets during histological analysis) [ Time Frame: 90±5 days post-transplant for sentinel Cell Pouch™ ]” Islets Independent Pathologist reported: ➢ a

Slide 24: Clinical Study Update (Safety)
Clinical Study Update (Safety) ENROLLMENT: 5 of the 7 patients have now been enrolled, implanted with Cell Pouches and are actively advancing through the transplantation phase of the study ➢ 5 of 7 patients have been implanted with the Cell Pouch ➢ 3 of 7 patients have received their first/one islet

Slide 25: Clinical Study Update (Efficacy)
Clinical Study Update (Efficacy) Highlighting some of the trial efficacy findings with focus on clinical benefits to the T1D patients, the following trends have also been observed as of the presentation of Sernova’s clinical investigator on January 15, 2021 at the ASTS Winter Symposium. EFFICACY (Se

Slide 26: Earlier First-in-Human Study
Earlier First-in-Human Study First-in-World Successful Proof-of-Concept Study Design ➢ T1D subjects with HU & a history of severe hypoglycemic episodes ➢ Open-label, single-arm ➢ Donor islet transplantation 2 – 24 weeks post Cell Pouch implantation ➢ Primary Endpoint: Safety post Cell Pouch implanta

Slide 27: Hemophilia A Program
Hemophilia A Program Estimated ➢ ~20 K patients across North America & EU Market ➢ ~$10 B orphan indication Benefits of Sernova’s Cell Pouch with factor VIII releasing cells: ➢ Patients receive regular infusions of missing Standard clotting factors (i.e. factor VIII) ➢ Reduce / eliminate factor of C

Slide 28: Thyroid Disease Program
Thyroid Disease Program Estimated ➢ 150,000 thyroidectomies performed annually in US ➢ ~$2.2 B market opportunity Market Benefits of Sernova’s Cell Pouch with Thyroid releasing cells: ➢ Patients require lifelong thyroid hormone ➢ Reduce / eliminate daily life replacement therapy Standard long thyroi

Slide 29: NEXT STEPS – Action Plan
NEXT STEPS – Action Plan ➢ Develop licensed/acquired local immune-protection technologies for Platform therapeutic cells Technology ➢ Advance local immune-protected diabetes stem cell technology in preparation for First-in-Man (FIM) study ➢ Expand existing strong worldwide multi-family patent portfo

Slide 30: Management Team
Management Team Dr. Philip Toleikis PRESIDENT & CEO ➢ 20+ years experience in biotech management & product development in pharmaceutical & combination products. ➢ Previous Angiotech VP R&D (achieved $2 B market cap; product revenue $200 M per year). David Swetlow CPA, CA Board of Directors CFO ➢ Fra

Slide 31: 700 Collip Circle, Suite 114 London, Ontario Canada
700 Collip Circle, Suite 114 London, Ontario Canada N6G 4X8 info@sernova.com www.sernova.com
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023